Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Holding PTGX?
Track your performance easily
PTGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.72 - $48.00
Previous Close$43.8
Volume384.30K
Average Volume (3M)682.95K
Market Cap
$2.58B
Enterprise Value$2.03B
Total Cash (Recent Filing)$564.04M
Total Debt (Recent Filing)$10.97M
Price to Earnings (P/E)16.7
Beta0.34
Next Earnings
Nov 06, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.63
Shares Outstanding58,904,585
10 Day Avg. Volume574,617
30 Day Avg. Volume682,945
Standard Deviation0.29
R-Squared0.15
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.77
Price to Sales (P/S)8.19
Price to Cash Flow (P/CF)2.40
P/FCF Ratio2.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit33.78
Enterprise Value/Ebitda12.07
Forecast
1Y Price Target
$50.83Price Target Upside15.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Protagonist Therapeutics News
PremiumCompany Announcements
Protagonist Therapeutics Board and Audit Committee Changes
Bulls Say, Bears Say
Bulls Say
Market PotentialRusfertide has the potential to tap into a multi-billion dollar market for polycythemia vera, representing a significant opportunity for growth.
Partnerships And CollaborationsCo-development agreements with Takeda and Johnson & Johnson validate the innovative platform and provide significant financial milestones and royalties.
Pipeline And Future GrowthThe diverse portfolio and multiple clinical trial successes suggest a strong pipeline that could generate substantial value in the future.
Bears Say
Clinical TrialsUnexpected safety concerns in ongoing clinical trials present significant risks.
Financial PerformanceOperating expenses were below consensus expectations, indicating potential financial challenges.
Partnership RisksThere is a risk that partner JNJ may decide not to pursue JNJ-2113, impacting future prospects.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $13.72 and its highest was $48.00 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 18 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.595 by $0.095.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -$0.58.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 58,904,587 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.595. Following the earnings report the stock price went up 1.174%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 202M.
---
Protagonist Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.83 (15.63% Upside)
$50.83 (15.63% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 531.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $631.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.70%
12-Months-Change
Fundamentals
Return on Equity
40.69%
Trailing 12-Months
Asset Growth
91.79%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$50.83
▲(15.63% Upside)
Technical Analysis
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
18/18 ratings generated profit
1 Year Average Return
+82.06%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +82.06% per trade.
---